Show simple item record

Inhibition of glycogen synthase kinase 3-b is sufficient but not required for airway smooth muscle hypertrophy.

dc.contributor.authorDeng, H
dc.contributor.authorHershenson, MB
dc.contributor.authorBentley, JK
dc.coverage.spatialUnited States
dc.date.accessioned2023-10-25T12:32:36Z
dc.date.available2023-10-25T12:32:36Z
dc.date.issued2008-04-11
dc.identifier.issn0021-9258
dc.identifier.issn1083-351X
dc.identifier.urihttps://www.ncbi.nlm.nih.gov/pubmed/18252708
dc.identifier.urihttps://hdl.handle.net/2027.42/191157en
dc.description.abstractWe examined the role of glycogen synthase kinase-3β (GSK-3β) inhibition in airway smooth muscle hypertrophy, a structural change found in patients with severe asthma. LiCl, SB216763, and specific small interfering RNA (siRNA) against GSK-3β, each of which inhibit GSK-3β activity or expression, increased human bronchial smooth muscle cell size, protein synthesis, and expression of the contractile proteins α-smooth muscle actin, myosin light chain kinase, smooth muscle myosin heavy chain, and SM22. Similar results were obtained following treatment of cells with cardiotrophin (CT)-1, a member of the interleukin-6 superfamily, and transforming growth factor (TGF)-β, a proasthmatic cytokine. GSK-3β inhibition increased mRNA expression of α-actin and transactivation of nuclear factors of activated T cells and serum response factor. siRNA against eukaryotic translation initiation factor 2Bε (eIF2Bε) attenuated LiCl- and SB216763-induced protein synthesis and expression of α-actin and SM22, indicating that eIF2B is required for GSK-3β-mediated airway smooth muscle hypertrophy. eIF2Bε siRNA also blocked CT-1- but not TGF-β-induced protein synthesis. Infection of human bronchial smooth muscle cells with pMSCV GSK-3β-A9, a retroviral vector encoding a constitutively active, nonphosphorylatable GSK-3β, blocked protein synthesis and α-actin expression induced by LiCl, SB216763, and CT-1 but not TGF-β. Finally, lungs from ovalbumin-sensitized and -challenged mice demonstrated increased α-actin and CT-1 mRNA expression, and airway myocytes isolated from ovalbumin-treated mice showed increased cell size and GSK-3β phosphorylation. These data suggest that inhibition of the GSK-3β/ eIF2Bε translational control pathway contributes to airway smooth muscle hypertrophy in vitro and in vivo. On the other hand, TGF-β-induced hypertrophy does not depend on GSK-3β/eIF2B signaling. © 2008 by The American Society for Biochemistry and Molecular Biology, Inc.
dc.format.mediumPrint-Electronic
dc.publisherElsevier
dc.rightsLicence for published version: Creative Commons Attribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectAnimals
dc.subjectAsthma
dc.subjectBronchi
dc.subjectCytokines
dc.subjectEnzyme Inhibitors
dc.subjectEukaryotic Initiation Factor-2B
dc.subjectGlycogen Synthase Kinase 3
dc.subjectGlycogen Synthase Kinase 3 beta
dc.subjectHumans
dc.subjectHypertrophy
dc.subjectIndoles
dc.subjectLithium Chloride
dc.subjectMaleimides
dc.subjectMice
dc.subjectMuscle Proteins
dc.subjectMuscle, Smooth
dc.subjectProtein Biosynthesis
dc.subjectRNA, Small Interfering
dc.subjectSignal Transduction
dc.titleInhibition of glycogen synthase kinase 3-b is sufficient but not required for airway smooth muscle hypertrophy.
dc.typeConference Paper
dc.identifier.pmid18252708
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/191157/2/10198.pdf
dc.identifier.doi10.1074/jbc.M800624200
dc.identifier.doihttps://dx.doi.org/10.7302/21546
dc.identifier.sourceProc Am Thorac Soc
dc.description.versionPublished version
dc.date.updated2023-10-25T12:32:32Z
dc.identifier.orcid0000-0001-9436-5593
dc.identifier.orcid0000-0001-8865-7979
dc.description.filedescriptionDescription of 10198.pdf : Published version
dc.identifier.volume4
dc.identifier.issue15
dc.identifier.startpage10198
dc.identifier.endpage10207
dc.identifier.name-orcidDeng, H
dc.identifier.name-orcidHershenson, MB; 0000-0001-9436-5593
dc.identifier.name-orcidBentley, JK; 0000-0001-8865-7979
dc.working.doi10.7302/21546en
dc.owningcollnamePediatrics and Communicable Diseases, Department of


Files in this item

Show simple item record

Licence for published version: Creative Commons Attribution 4.0 International
Except where otherwise noted, this item's license is described as Licence for published version: Creative Commons Attribution 4.0 International

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.